The tumor-specific DNA markers including point mutations in EGFR or BRAF genes, rearrangements involving ALK or ROS1 genes and fusions of NTRK1/2/3 genes along with tumor mutation burden (TMB) and PDL-1 RNA expression serve as guides in proper therapy selection. This evidence concerns the gene BRAF and neoplasm.